Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial

Blood 2026 Open access

Read full text
Authors: Jeff P. Sharman, Luca Laurenti, E. Ferrant, Luis Felipe Casado Montero, Stephen P. Mulligan, Rosemary Anne Harrup, Stephen Opat, Adalberto Ibatici, R Marasca, Paolo Sportoletti, Maria Thadani-Mulero, Oscar Cazares
+6 more Weize Huang, Yanwen Jiang, Emma Clark, Hyun Yong Jin, Michelle Boyer, Franck Morschhauser
DOI: 10.1182/blood.2025030630
Cited by: 1
References: 24

Abstract

ABSTRACT: The phase 3 CRISTALLO trial compared first-line fixed-duration venetoclax-obinutuzumab (VenO) vs fludarabine, cyclophosphamide, and rituximab (FCR)/bendamustine-rituximab (BR) in patients with chronic lymphocytic leukemia (CLL), using undetectable minimal residual disease (uMRD) as the sole primary end point. Previously untreated patients with a cumulative illness rating scale score ≤6 and creatinine clearance ≥70 mL/min without del(17p)/TP53 mutations were randomized 1:1 to VenO or FCR/BR. The primary end point was uMRD (

Fields of Study & Subjects

Chronic Lymphocytic Leukemia Research Economic and Financial Impacts of Cancer Advanced Breast Cancer Therapies

Publication details

Journal / source
Blood
Publisher
American Society of Hematology
Volume
147
Issue
24
Pages
2895–2904
Publication date
2 March 2026
Language
EN